JP2024119853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024119853A5 JP2024119853A5 JP2024083589A JP2024083589A JP2024119853A5 JP 2024119853 A5 JP2024119853 A5 JP 2024119853A5 JP 2024083589 A JP2024083589 A JP 2024083589A JP 2024083589 A JP2024083589 A JP 2024083589A JP 2024119853 A5 JP2024119853 A5 JP 2024119853A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720234P | 2018-08-21 | 2018-08-21 | |
| US62/720,234 | 2018-08-21 | ||
| PCT/US2019/047573 WO2020041520A1 (en) | 2018-08-21 | 2019-08-21 | Monoclonal antibodies against human tim-3 |
| JP2021502951A JP7543247B2 (ja) | 2018-08-21 | 2019-08-21 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502951A Division JP7543247B2 (ja) | 2018-08-21 | 2019-08-21 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024119853A JP2024119853A (ja) | 2024-09-03 |
| JP2024119853A5 true JP2024119853A5 (enExample) | 2025-03-14 |
Family
ID=69591459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502951A Active JP7543247B2 (ja) | 2018-08-21 | 2019-08-21 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
| JP2024083589A Pending JP2024119853A (ja) | 2018-08-21 | 2024-05-22 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502951A Active JP7543247B2 (ja) | 2018-08-21 | 2019-08-21 | ヒトＴｉｍ－３に対するモノクローナル抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12134645B2 (enExample) |
| EP (1) | EP3841125A4 (enExample) |
| JP (2) | JP7543247B2 (enExample) |
| KR (1) | KR20210045999A (enExample) |
| CN (3) | CN112566936B (enExample) |
| AU (1) | AU2019325558A1 (enExample) |
| BR (1) | BR112021003018A2 (enExample) |
| CA (1) | CA3108879A1 (enExample) |
| IL (1) | IL280757A (enExample) |
| MX (1) | MX2020013428A (enExample) |
| NZ (1) | NZ770219A (enExample) |
| SG (1) | SG11202012148RA (enExample) |
| WO (1) | WO2020041520A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202012148RA (en) * | 2018-08-21 | 2021-01-28 | Albert Einstein College Medicine | Monoclonal antibodies against human tim-3 |
| WO2021175191A1 (zh) * | 2020-03-02 | 2021-09-10 | 信达生物制药(苏州)有限公司 | 抗tim-3抗体及其用途 |
| JP2024516616A (ja) | 2021-04-23 | 2024-04-16 | スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． | Ｔｉｍ－３を標的とする抗体及びその使用 |
| CN118871129A (zh) | 2022-03-14 | 2024-10-29 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与去甲基化药物的药物组合 |
| WO2023174408A1 (zh) * | 2022-03-18 | 2023-09-21 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与抗pd-l1抗体的药物组合 |
| WO2023217268A1 (zh) | 2022-05-13 | 2023-11-16 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与抗pd-1抗体的药物组合 |
| CN119789867A (zh) * | 2022-09-06 | 2025-04-08 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
| CN120752053A (zh) * | 2023-03-03 | 2025-10-03 | 正大天晴药业集团南京顺欣制药有限公司 | 含抗tim-3抗体的药物组合 |
| WO2025056005A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 抗tim-3抗体的药物组合物及用途 |
| WO2025056014A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| KR20060089732A (ko) | 2003-10-03 | 2006-08-09 | 브라이엄 앤드 위민즈 하스피틀 | Ｔｉｍ-3 리간드 및 그의 방법 |
| AU2004292180A1 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
| DE602006019565D1 (de) * | 2005-03-31 | 2011-02-24 | Biomedics Inc | Monoklonaler anti-cd20-antikörper |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2162471A1 (en) | 2007-06-08 | 2010-03-17 | Université de la Méditerranée | Compositions and methods for treating pancreatic tumors |
| KR20130036192A (ko) | 2010-02-11 | 2013-04-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법 |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| US9321833B2 (en) | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| HRP20211820T1 (hr) | 2016-04-12 | 2022-03-04 | Symphogen A/S | Anti-tim-3 protutijela i pripravci |
| SG10201911972QA (en) | 2016-07-14 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| EP3970749A1 (en) * | 2016-08-26 | 2022-03-23 | BeiGene, Ltd. | Anti-tim-3 antibodies and use thereof |
| MA46113A (fr) | 2016-11-01 | 2019-07-10 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3) |
| SG11202012148RA (en) * | 2018-08-21 | 2021-01-28 | Albert Einstein College Medicine | Monoclonal antibodies against human tim-3 |
-
2019
- 2019-08-21 SG SG11202012148RA patent/SG11202012148RA/en unknown
- 2019-08-21 MX MX2020013428A patent/MX2020013428A/es unknown
- 2019-08-21 WO PCT/US2019/047573 patent/WO2020041520A1/en not_active Ceased
- 2019-08-21 CA CA3108879A patent/CA3108879A1/en active Pending
- 2019-08-21 AU AU2019325558A patent/AU2019325558A1/en active Pending
- 2019-08-21 BR BR112021003018-2A patent/BR112021003018A2/pt unknown
- 2019-08-21 US US17/270,405 patent/US12134645B2/en active Active
- 2019-08-21 KR KR1020217004986A patent/KR20210045999A/ko active Pending
- 2019-08-21 NZ NZ770219A patent/NZ770219A/en unknown
- 2019-08-21 CN CN201980037800.1A patent/CN112566936B/zh active Active
- 2019-08-21 JP JP2021502951A patent/JP7543247B2/ja active Active
- 2019-08-21 CN CN202410802960.3A patent/CN118667020A/zh active Pending
- 2019-08-21 EP EP19852182.5A patent/EP3841125A4/en active Pending
- 2019-08-21 CN CN202410802940.6A patent/CN118667019A/zh active Pending
-
2021
- 2021-02-09 IL IL280757A patent/IL280757A/en unknown
-
2024
- 2024-05-22 JP JP2024083589A patent/JP2024119853A/ja active Pending
- 2024-10-02 US US18/904,972 patent/US20250034248A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024119853A5 (enExample) | ||
| ElBakri et al. | The state of antibody therapy | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JPWO2019175216A5 (enExample) | ||
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JPWO2019175220A5 (enExample) | ||
| JPWO2019175217A5 (enExample) | ||
| JPWO2019175224A5 (enExample) | ||
| JPWO2019175222A5 (enExample) | ||
| JPWO2019175215A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JPWO2019175226A5 (enExample) | ||
| JPWO2019175223A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2024016024A5 (enExample) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| JP2020513759A5 (enExample) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2025130076A5 (enExample) | ||
| JPWO2020041520A5 (enExample) | ||
| JPWO2020234399A5 (enExample) | ||
| CN115190887A (zh) | 结合cd47的抗原结合多肽及用途 | |
| JPWO2022067262A5 (enExample) | ||
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use |